Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines

European Journal of Cancer

Volumn 35, Issue 6, 1999, Pages 1027-1034

  Murakami, J ^a   Nagai, N ^a   Shigemasa, K ^a   Ohama, K ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Enhancement of cisplatin; Inhibition of cell growth; RTI; Telomerase; Telomere

Indexed keywords

CISPLATIN; DIDANOSINE; PROTEIN P21; PROTEIN P53; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELOMERASE; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ARTICLE; CANCER CELL CULTURE; CELL AGING; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIUM CARCINOMA; ENZYME INHIBITION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE;

BLOTTING, SOUTHERN; CELL DIVISION; CYSTADENOCARCINOMA; DIDANOSINE; ENDOMETRIAL NEOPLASMS; FEMALE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; THYMINE NUCLEOTIDES; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; ZIDOVUDINE;

EID: 0033153293     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00037-4     Document Type: Article

References (33)

1. Hiyama E., Gollahon L., Kataoka T., Kuroi K., Yokoyama T., Gazdar A.F. Telomerase activity in human breast tumours. J. Natl. Cancer. 88:1996;116-122.
2. Baccetti S., Counter C.M. Telomeres and telomerase in human cancer (review). Int. Natl. J. Oncol. 7:1995;423-432.
3. Breslow R.A., Shay J.W., Gazdar A.F., Srivastava S. Telomerase and early detection of cancer: a National Cancer Institute Workshop. J. Natl. Cancer Inst. 89:1997;618-623.
4. Shay J.W., Gazdar A.F. Telomerase in the early detection of cancer. J. Clin. Pathol. 50:1997;106-109.
5. Murakami J., Nagai N., Ohama K. Diagnostic significance of the telomerase activity in ovarian tumours. Cytometry Res. 7:1997;39-44.
6. Holt S.E., Aisner D.L., Shay J.W., Wright W.E. Lack of cell cycle regulation of activity in human cells. Proc. Natl. Acad. Sci. USA. 94:1997;10687-10692.
7. Belair C.D., Yeager T.R., Lopez P.M., Reznikof C.A. Telomerase activity: A biomarker of cell proliferation, not malignant transformation. Proc. Nad. Acad. Sci. USA. 94:1997;13677-13682.
8. Strahl C., Blackburn E.H. The effects of nucleoside analogues on telomerase and telomeres in Tetrahymena. Nucleic Acids Research. 22:1994;893-900.
9. Yegorov Y.E., Chernov D.N., Akimov S.S., Bolsheva N.L., Krayevsky A.A., Zelenin A.V. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts. FEBS Letters. 389:1996;115-118.
10. Strahl C., Blackburn E.H. Effect of reverse transcriptase inhibitor on telomere length and telomerase activity in two immortalized human cell line. Mol. and Cell. Biol. 16:1996;53-65.
11. Parra I., Flores C., Adrian D., Windle B. AZT induces high frequency, rapid amplification of entrometric DNA. Cytogenet. Cell Genet. 76:1997;128-133.
12. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
13. Kim N.W., Wu F. Advances in quantification and characterisation of telomerase activity by the telomeric repeat amplification protocol(TRAP). Nucleic Acids Res. 25:1997;2595-2597.
14. Mosmann T. Rapid calorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
15. Moyzis R.X., Buckingham J.M., Cram L.S.et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. USA. 85:1988;6622-6626.
16. Hiyama K., Ishioka S., Shirotoni Y.et al. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene. 10:1995;937-944.
17. Shigemasa K., Hu C., West C.M.et al. p21: a monitor of p53 dysfunction in ovarian neoplasia. Int. J. Gynecol. Cancer. 7:1997;296-303.
18. Norton J.M., Piatyszek A.P., Wright W.E., Shay J.W., Corey D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotechnology. 14:1996;615-618.
19. Feng J., Funk W.D., Wang S.S.et al. The RNA component of human telomerase. Science. 269:1995;1236-1241.
20. Hamilton S.E., Pitts A.E., Katipally R.R.et al. Identification of determinants for inhibition binding within the RNA active site of human telomerase using RNA scanning. Biochemistry. 36:1997;11873-11880.
21. Sun D., Thompson B., Cathers B.E.et al. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40:1997;2113-2116.
22. Li H., Zhao L.-L., Funder J.W., Liu J.-P. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J. Biol. Chem. 272:1997;16729-16732.
23. Kanazawa Y., Ohkawa K., Ueda K.et al. Hammer head ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophy. Res. Comm. 225:1996;570-576.
24. Pai R.B., Pai B., Kukhanova M., Dutschman G.E., Guo X., Cheng Y.C. Telomerase from human leukemia cells: properties and its interaction with deoxynucleoside analogues. Cancer Res. 58:1998;1909-1913.
25. Melana S.M., Holland J.F., Pogo B.G. Inhibition of cell growth and telomerases activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4:1998;693-696.
26. Gomez D.E., Tejera A.M., Olivero O.A. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment. Biochem. Biophys. Res. Commun. 246:1998;107-110.
27. Bottalico C., Lorusso V., Brandi M.et al. Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. Anticancer Res. 16:1996;3865-3869.
28. Soulie R., Bensmaine A., Garrino C.et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur. J. Cancer. 33:1997;1400-1406.
29. Chollet P., Bensmaine M.A., Brienza S.et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oncol. 7:1996;1065-1070.
30. Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann. NY Acad. Sci. 13:1996;292-305.
31. Burger A.M., Double J.A., Newell D.R. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer. 33:1997;638-644.
32. Bedford P., Fichtinger-Schepman A.M.J., Shellard S.A., Walker M.C., Masters J.R.W., Hill B.T. Differential repair of platinum-DNA adducts in human bladder and testicular tumour continuous cell lines. Cancer Res. 48:1988;3019-3024.
33. Kondo Y., Kondo S., Tanaka Y., Haqqi T., Barna B.P., Cowell J.K. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene. 16:1998;2243-2248.